

PEER-REVIEW REPORT

Name of journal: World Journal of Clinical Cases

Manuscript NO: 56691

Title: Idiopathic multicentric Castleman disease with pulmonary and cutaneous lesions treated with tocilizumab: A case report

Reviewer's code: 02804922

Position: Editorial Board

Academic degree: PhD

Professional title: Professor

Reviewer's Country/Territory: Mexico

Author's Country/Territory: China

Manuscript submission date: 2020-05-18

Reviewer chosen by: AI Technique

Reviewer accepted review: 2020-05-26 04:25

Reviewer performed review: 2020-05-27 06:48

Review time: 1 Day and 2 Hours

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input checked="" type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
Peer-reviewer statements	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
<https://www.wjgnet.com>

SPECIFIC COMMENTS TO AUTHORS

The manuscript of Ping-Yang Han and coworkers is well written and correctly presented, however minimal changes are necessary to improve its quality. The title must be changed to increase the accuracy, and the antibody used must be included in the keywords, the grammar must be reviewed in lines 249, 181, 112 and 98, at last in the discussion section the authors must discuss the difference in the differences between Siltuximab and Tocilizumab